Trial Profile

NEPTUNE: Enhancement of immunotherapy combining avelumab and repeat doses of radium-223 in ER+ve, HER2-ve metastatic breast cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 15 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary) ; Radium 223 chloride (Primary)
Indications Advanced breast cancer; Bone metastases; HER2 negative breast cancer
Focus Adverse reactions; Proof of concept; Therapeutic Use
Acronyms NEPTUNE

Most Recent Events

16 Jun 2023 Planned End Date changed from 15 Jun 2023 to 1 Jun 2027.
16 Jun 2023 Status changed from completed to active, no longer recruiting.
06 Oct 2022 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com